Business

Valeant sets sights on Mideast, North Africa with Amoun purchase

Valeant Pharmaceuticals International, Inc. says it will buy a major Egyptian pharmaceutical company for about $800 million US as a platform for further expansion in the Middle East and North Africa.

Deal would be biggest acquisition since Salix Pharmaceuticals

Valeant Pharmaceuticals International, Inc. says it will buy a major Egyptian pharmaceutical company for about $800 million US as a platform for further expansion in the Middle East and North Africa.

The Quebec-based company says it has a definite agreement to buy Amoun Pharmaceutical from Mercury (Cayman) Holdings.

The deal will include Amoun's manufacturing plant, which Valeant says is one of the largest and most modern in the region.

Amoun also has branded products for the treatment of hypertension, infections and diarrhea.

If the transaction closes as planned, it will be Valeant's biggest acquisition since it paid $11.1 billion US to buy Salix Pharmaceuticals in a deal that closed April 1 after a bidding war with Irish rival Endo International.

Comments

To encourage thoughtful and respectful conversations, first and last names will appear with each submission to CBC/Radio-Canada's online communities (except in children and youth-oriented communities). Pseudonyms will no longer be permitted.

By submitting a comment, you accept that CBC has the right to reproduce and publish that comment in whole or in part, in any manner CBC chooses. Please note that CBC does not endorse the opinions expressed in comments. Comments on this story are moderated according to our Submission Guidelines. Comments are welcome while open. We reserve the right to close comments at any time.

now